论文部分内容阅读
目的探讨骨桥蛋白(OPN)联合血清CA125和CA19-9水平对子宫内膜异位症的诊断价值。方法2005年1月-2008年12月采集45例子宫内膜异位症患者及45名健康妇女自愿捐赠的血清样品,分别采用ELISA法及化学发光法检测OPN、CA125、CA19-9水平。结果与健康妇女相比,子宫内膜异位症患者血清OPN和CA125、CA19-9含量明显升高(P<0.01)。重度组(美国生育学会分期Ⅲ、Ⅴ期)子宫内膜异位症患者OPN和CA125、CA19-9明显高于轻度组(Ⅰ、Ⅱ期)(P<0.01)。结论OPN、CA19-9可作为子宫内膜异位症诊断及病情监测的临床指标,联合CA125检测可提高其临床应用价值。
Objective To investigate the diagnostic value of osteopontin (OPN) combined with serum CA125 and CA19-9 levels in patients with endometriosis. Methods Serum samples from 45 patients with endometriosis and 45 healthy women were collected from January 2005 to December 2008. The serum levels of OPN, CA125 and CA19-9 were detected by ELISA and chemiluminescence respectively. Results Compared with healthy women, the serum levels of OPN, CA125 and CA19-9 in patients with endometriosis were significantly increased (P <0.01). The severity of OPN, CA125 and CA19-9 in patients with severe endometriosis (Stage Ⅲ and Ⅴ of American Fertility Society) were significantly higher than those in mild stage (Ⅰ, Ⅱ) (P <0.01). Conclusion OPN and CA19-9 can be used as clinical indicators for the diagnosis and disease surveillance of endometriosis. Combined with CA125 detection, it can improve the clinical value.